Comments
Lupin Limited has received United States Food and Drug Administration (USFDA) approval for its abbreviated new drug application for Turqoz (norgestrel and ethinyl estradiol tablets USP) 0.3 mg/0.03 mg.
Lupin can market a generic version of Wyeth Pharmaceuticals LLC’s Lo/Ovral-28, which registers an estimated annual sales of $34 million in the US. The generic product will be manufactured at Lupin’s Pithampur facility in India.
Lupin shares fell by 0.73 per cent to Rs 981 at 12.24 pm on BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.